Kieron Dunleavy, MD, from the National Cancer Institute, Bethesda, MD, discusses ibrutinib in the treatment of diffuse large B-cell lymphoma at the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2017, held in Vancouver, BC, Canada. There are two subtypes of diffuse large B-cell lymphoma; germinal center B-cell like (GCB) and activated B-cell-like (ABC). An important characteristic of the ABC type is activation of the NF-κB pathway, one step involving BTK. Ibrutinib is an agent that targets BTK, and there have been multiple studies investigating this in the relapsed and refractory setting. This video was supported by Janssen Pharmaceuticals (a Johnson & Johnson Company) through an unrestricted educational grant to Magdalen Medical Publishing. The company had no influence on the production of this content.